L
Lucy Claire Davies
Researcher at University of Sydney
Publications - 17
Citations - 1499
Lucy Claire Davies is an academic researcher from University of Sydney. The author has contributed to research in topics: Quality of life & Cancer. The author has an hindex of 9, co-authored 15 publications receiving 1126 citations. Previous affiliations of Lucy Claire Davies include National Health and Medical Research Council.
Papers
More filters
Journal ArticleDOI
Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial
Andrew R. L. Stevenson,Andrew R. L. Stevenson,Michael J. Solomon,John W. Lumley,Peter J. Hewett,Andrew D. Clouston,Andrew D. Clouston,Val Gebski,Lucy Claire Davies,Kate Wilson,Wendy Hague,John Simes +11 more
TL;DR: Among patients with T1-T3 rectal tumors, noninferiority of laparoscopic surgery compared with open surgery for successful resection was not established, and these findings do not provide sufficient evidence for the routine use of lapARoscopic surgery.
Journal ArticleDOI
Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration.
Lisa M. Askie,Brian A Darlow,Neil N. Finer,Barbara Schmidt,Barbara Schmidt,Ben Stenson,William Tarnow-Mordi,Peter G Davis,Waldemar A. Carlo,Peter Brocklehurst,Peter Brocklehurst,Lucy Claire Davies,Abhik Das,Wade Rich,Marie G. Gantz,Robin S. Roberts,Robin K. Whyte,Lorrie Costantini,Christian F. Poets,Elizabeth Asztalos,Malcolm R. Battin,Henry L. Halliday,Neil Marlow,Win Tin,Andrew J. King,Edmund Juszczak,Colin J Morley,Lex W. Doyle,Val Gebski,Kylie E Hunter,R. J. Simes +30 more
TL;DR: There was no significant difference between a lower SpO2 target range compared with a higher SpO 2 target range on the primary composite outcome of death or major disability at a corrected age of 18 to 24 months.
Journal ArticleDOI
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Chee Khoon Lee,Chee Khoon Lee,Lucy Claire Davies,Yi-Long Wu,Tetsuya Mitsudomi,Akira Inoue,Rafael Rosell,Caicun Zhou,Kazuhiko Nakagawa,Sumitra Thongprasert,Masahiro Fukuoka,Sarah J. Lord,Ian C. Marschner,Ian C. Marschner,Yu-Kang Tu,Richard J. Gralla,Val Gebski,Tony Mok,James Chih-Hsin Yang +18 more
TL;DR: There is no relative OS advantage with frontline gefitinib or erlotinib vs chemotherapy in EGFR -mutated NSCLC, and EGFR-TKI statistically significantly prolonged progression-free survival (PFS) overall.
Journal ArticleDOI
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Rosie Bradley,Jeremy P Braybrooke,Richard Gray,Robert Kerrin Hills,Zulian Liu,Hongchao Pan,Richard Peto,David Dodwell,Paul McGale,Carolyn W. Taylor,Prudence A. Francis,Michael Gnant,Francesco Perrone,Meredith M. Regan,Richard B. Berry,Clare Boddington,Mike Clarke,C Davies,Lucy Claire Davies,F Duane,Vaughan Evans,Jo Gay,Lucy Gettins,Jon Godwin,S James,Hui Li,Elizabeth MacKinnon,Gurdeep S. Mannu,Theresa McHugh,Philip Morris,Simon Read,Ewan Straiton,Raimund Jakesz,Christian Fesl,Olivia Pagani,Richard D. Gelber,Michelino De Laurentiis,Sabino De Placido,Ciro Gallo,Kathy S. Albain,Stewart J. Anderson,Rodrigo Arriagada,John M. S. Bartlett,Elizabeth Bergsten-Nordström,Judith M Bliss,Etienne Brain,Lisa A. Carey,Robert E. Coleman,Jack Cuzick,Nancy E. Davidson,Lucia Del Mastro,Angelo Di Leo,James J. Dignam,Mitch Dowsett,Bent Ejlertsen,Matthew P. Goetz,Pamela J. Goodwin,Pat Halpin-Murphy,Dan Hayes,Catherine Hill,Reshma Jagsi,Wolfgang Janni,Sibylle Loibl,Eleftherios P. Mamounas,Miguel Martin,Hirofumi Mukai,Valentina Nekljudova,Larry Norton,Yasuo Ohashi,Lori J. Pierce,Philip Poortmans,Kathleen I. Pritchard,Vinod Raina,Daniel Rea,John F.R. Robertson,Emiel J. Th. Rutgers,Tanja Spanic,Joseph A. Sparano,Guenther G. Steger,Gong Tang,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Xiang Wang,Tim Whelan,Nicholas Wilcken,Norman Wolmark,David Cameron,Jonas Bergh,Sandra M. Swain +89 more
TL;DR: Whether premenopausal women treated with ovarian suppression benefit from aromatase inhibitors is investigated, as distant recurrence invariably results in death from breast cancer several years after the occurrence, whereas locoregional recurrence and new contralateral breast cancer are not usually fatal.
Journal ArticleDOI
Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm.
Andrew G. Sherrah,Sarah Andvik,Denise van der Linde,Lucy Claire Davies,Paul G. Bannon,Ratnasari Padang,Michael P. Vallely,Michael K. Wilson,Anthony C Keech,Richmond W. Jeremy +9 more
TL;DR: Clinical outcomes for MFS and NS-TAA are similar but worse than BAV, and management of NS- TAA, including surgical intervention, should be similar to that of MFS.